Notwithstanding encouraging clinical evidence, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing significant difficulty from pharmacy benefit managers. Such companies are often building obstacles to reimbursement, including high price requirements and prior authorization that limit patient av